Microbot Medical Successfully Completes an Extensive Pre-Clinical Study Performed in the US
29 Junho 2023 - 9:30AM
Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY®
Robotic Surgical System, the first single-use endovascular robotic
surgical system, today announced the successful completion of an
extended pre-clinical study held by leading key opinion leaders
("KOLs") at a New York-based research lab.
A team of leading interventional radiologists
utilized the system and performed dozens of catheterizations,
including the utilization of the system’s remote operation
capabilities, to pre-determined vascular targets, with a 100%
success rate of reaching the intended target with no observable
on-site complications.
In addition, it was the first study that the
Company allowed participants of leading organizations from the
medical industry to join.
Very similar to previous studies, the Company
received positive real-time user feedback, including with respect
to the intuitiveness of the system, ease of set up and use, and
value added that they see with the ability to control procedures
remotely via the LIBERTY Robotic Surgical System’s remote
controller. Moreover, the Company received valuable input from the
industry participants, which aligned to the value proposition
LIBERTY is expected to bring to the market and which the Company
believes will assist in the future adoption of LIBERTY when
commercialized.
"We continue to expand our close relationships
with international KOLs and, for the first time, we incorporated
executives from the medical industry. We believe that our LIBERTY
Robotic Surgical System has the potential to benefit patients,
physicians and commercial organizations from the medical field as
we continue to advance in the regulatory process with the FDA and
other regions across the world. Following several successful
studies in Europe, and now in the US, the support and endorsement
we receive has great value for our future commercial plans,"
commented Harel Gadot, Microbot's Chief Executive Officer.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, with the goals of
improving clinical outcomes for patients and increasing
accessibility through the natural and artificial lumens within the
human body.
The LIBERTY® Robotic Surgical System aims to
improve the way surgical robotics are being used in endovascular
procedures today, by eliminating the need for large, cumbersome,
and expensive capital equipment, while reducing radiation exposure
and physician strain. The Company believes the LIBERTY® Robotic
Surgical System’s remote operation has the potential to be the
first system to democratize endovascular interventional
procedures.Further information about Microbot Medical is available
at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of
LIBERTY®, the outcome of its studies to evaluate LIBERTY®, whether
the Company’s core business focus program and cost reduction plan
are sufficient to enable the Company to continue to focus on its
LIBERTY technology while it stabilizes its financial condition and
seeks additional working capital , any failure or inability to
recruit physicians and clinicians to serve as primary investigators
to conduct regulatory studies which could adversely affect or delay
such studies, uncertainty in the results of pre-clinical and
clinical trials or regulatory pathways and regulatory approvals,
uncertainty resulting from the COVID-19 pandemic, need and ability
to obtain future capital, and maintenance of intellectual property
rights. Additional information on risks facing Microbot Medical can
be found under the heading “Risk Factors” in Microbot Medical’s
periodic reports filed with the Securities and Exchange Commission
(SEC), which are available on the SEC’s web site at www.sec.gov.
Microbot Medical disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Contact:
Michal Efraty+972-(0)52-3044404IR@microbotmedical.com
Microbot Medical (NASDAQ:MBOT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Microbot Medical (NASDAQ:MBOT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024